Anne K.
- Country
- France
- Department
- Oncologie Médicale
Research Overview
- Randomized Phase II/III Study of Cabozantinib Maintenance Versus Best Supportive Care in Osteosarcoma Patients After First‑Line Chemotherapy (FOSTER‑CabOS)
- Phase 2 Multicentre Randomized Trial of Mifamurtide with Post-Operative Chemotherapy in High-Risk Osteosarcoma Patients
- Adjuvant Pembrolizumab and Paclitaxel Versus Surveillance in Early Triple-Negative Breast Cancer with High Stromal Tumor-Infiltrating Lymphocytes
Data & Insights
Has run more than one trial at 44 of 143 partner sites.
Specializations
Breast Cancer Specialization
This investigator focuses on advanced therapeutic approaches for various breast cancer subtypes, particularly triple-negative breast cancer (TNBC) and hormone receptor-positive breast cancer.
- Post-operative treatment strategies
- Hormone therapy optimization
- Immunotherapy applications
Their research encompasses adjuvant therapy combinations and targeted treatments for high-risk patients.
Immunotherapy Research
The investigator specializes in innovative immunotherapeutic approaches, with particular attention to pembrolizumab-based treatments and their integration with conventional therapies.
- Chemoimmunotherapy combinations
- Treatment response assessment
- Tumor-infiltrating lymphocyte analysis
Their work explores personalized immunotherapy strategies based on biological markers.
Bone Cancer Treatment
The investigator conducts research in high-risk osteosarcoma treatment, focusing on novel therapeutic combinations for patients with metastatic disease.
- Targeted therapy development
- Post-operative treatment protocols
- High-risk patient management
Their studies evaluate innovative approaches for improving survival outcomes in bone cancer patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.